(Reuters) -- Royal DSM, the
global Life Sciences and Materials Sciences company, announced that its indirect
wholly-owned subsidiary, Biomedical Acquisition Corporation, has commenced its
previously announced tender offer for all outstanding shares of common stock of
The Kensey Nash board of directors has unanimously
determined that, among other things, the offer is fair to and in the best
interests of Kensey Nash's stockholders and unanimously recommends that Kensey
Nash's stockholders accept the offer and tender their shares.
The tender offer is scheduled to expire at 12:00 midnight at the end of
Monday, 18 June 2012, unless the offer is extended.
Complete terms and conditions of the tender offer are set forth in the Offer
to Purchase, Letter of Transmittal and other related materials that will be
filed by DSM and Biomedical Acquisition Corporation on 21 May
Kensey Nash is a medical device company primarily focused on
regenerative medicine utilizing its proprietary collagen and synthetic polymer
technology. The company is recognized as a leader for innovative product
development and unique technology in the field of resorbable biomaterials.
The company has an extensive range of products, which are sold through strategic
partners in multiple medical markets, including the cardiology, orthopedic,
sports medicine, spine, trauma, craniomaxillofacial and general surgery markets.